Pediatric Schizophrenia Efficacy and Safety Study

A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia

Efficacy and Safety study of Lurasidone in pediatric patients.

Study Overview

• Status: Completed
• Conditions: Schizophrenia
• Intervention / Treatment: Drug: Lurasidone 40 mg; Drug: Lurasidone 80 mg; Drug: Placebo 40 or 80 mg

Detailed Description

To evaluate the efficacy of lurasidone (40 mg/day and 80 mg/day) compared with placebo in adolescent subjects with schizophrenia (diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR] criteria) as measured by the change from Baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 6.

• Study Type: Interventional
• Enrollment (Actual): 327
• Phase: Phase 3

Contacts and Locations

Study Locations

• Belgium
  • Bruxelles, Belgium, 1090
    • Universitair Ziekenhuis Brussel
• Bulgaria
  • Ruse, Bulgaria, 7003
    • MHC - Ruse, EOOD
  • Sofia, Bulgaria, 1431
    • UMHAT "Alexandrovska" EAD
  • Targovishte, Bulgaria, 7700
    • MHAT-Targovishte, AD
  • Varna, Bulgaria, 9003
    • MHAT 'Sv. Marina', EAD
• Colombia
  • Barranquilla, Colombia
    • Centro de Investigaciones y Proyectos en Neurociencias CIPNA
  • Bello, Colombia, 0000
    • E.S.E. Hospital Mental de Antioquia
  • Bogota, Colombia, 00000
    • Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda
• France
  • Nice, France, 06200
    • Hôpitaux Pédiatriques de Nice CHU-Lenval
  • Loire Atlantique
    • Nantes Cedex 1, Loire Atlantique, France, 44093
      • CHU Nantes - Hopital Mere-Enfant
• Hungary
  • Budapest, Hungary, 1021
    • Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert
  • Gyula, Hungary, 5700
    • Békés Megyei Pándy Kálmán Kórház
• Korea, Republic of
  • Incheon, Korea, Republic of, 400-711
    • Inha University Hospital
  • Jeonju-si, Korea, Republic of, 561-712
    • Chonbuk National University Hospital
  • Seoul, Korea, Republic of, 120-752
    • Severance Hospital, Yonsei University Health System
• Malaysia
  • Kuala Lumpur
    • Lembah Pantai, Kuala Lumpur, Malaysia, 59100
      • University Malaya Medical Centre
• Mexico
  • Culiacan, Mexico, 80020
    • Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.
  • Monterrey, Mexico, 64000
    • Accelerium S. de R.L. de C.V.
  • Monterrey, Mexico, 64710
    • Instituto de Informacion de Investigacion en Salud Mental
• Philippines
  • Daveo City, Philippines, 8000
    • Alexian Brothers Health and Wellness Center
  • Iloilo City, Philippines, 5000
    • West Visayas State University Medical Center
  • Mandaluyong City, Philippines, 1553
    • National Center for Mental Health
  • Quezon City, Philippines, 1101
    • Veterans Memorial Medical Center
• Poland
  • Torun, Poland, 87-100
    • Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu
  • Tyniec Maly, Poland, 55-040
    • NZOZ Poradnia Zdrowia Psychicznego
  • Warszawa, Poland, 02-957
    • Instytut Psychiatrii i Neurologii
• Puerto Rico
  • Caguas, Puerto Rico, 00725
    • Centro de Investigacion Clinica Psiquiatrica
  • Ponce, Puerto Rico, 00731
    • Centro de Investigacion Clinica Psiquiatrica
  • San Juan, Puerto Rico, 00918
    • INSPIRA Clinical Research
• Romania
  • Bucuresti, Romania, 041914
    • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
  • Iasi, Romania, 700282
    • Spitalul Clinic de Psihiatrie Socola
  • Timisoara, Romania, 300239
    • Spitalul Clinic de Urgenta pentru Copii "Louis Turcanu" Timisoara
• Russian Federation
  • Ekaterinburg, Russian Federation, 620030
    • Sverdlov Regional Psychiatric Clinical Hospital
  • Lipetsk, Russian Federation, 399083
    • Regional Government Institution Kipetsk Regional Psychoneurology Hospital
  • Novgorod, Russian Federation, 603155
    • Nizhny Novgorod Regional State Institution of Healthcare
  • Saratov, Russian Federation, 410060
    • SHI Regional Clinical Psychiatry Hospital of St. Sofia
  • St. Petersburg, Russian Federation, 190005
    • St. Petersburg State Healthcare Institution (SPSHI)
  • St. Petersburg, Russian Federation, 192019
    • FSBI "Bekhterev Psychoneurological Research Institute SPb Russia"
  • Tomsk, Russian Federation, 634014
    • FSBSI "Scientific Research Institute of Mental Health"
• Spain
  • Barcelona, Spain, 08950
    • Hospital Sant Joan de Déu
  • Málaga
    • Torremolinos, Málaga, Spain, 29620
      • Hospital Marítimo de Torremolinos
• Ukraine
  • Ivano Frankivsk, Ukraine, 76014
    • RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU
  • Kharkiv, Ukraine, 61068
    • SI Institute of Neurology, Psychiatry and Narcology of NAMSU
  • Kharkiv, Ukraine, 61153
    • SI Institute of Children and Adolescents Healthcare of NAMSU
  • Kherson,Vil. Stepanivka, Ukraine, 73488
    • CI Kherson Regional Psychiatric Hospital of Kherson RC
  • Kyiv, Ukraine, 04080
    • TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions
  • Lviv, Ukraine, 79021
    • CI Lviv Regional Clinical Psychiatric Hospital
  • Odesa, Ukraine, 65006
    • CI Odesa Regional Medical Center of Mental Health
  • Poltava, Ukraine, 36006
    • O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy
  • Ternopil, Ukraine, 46020
    • Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU
  • Vinnytsia, Ukraine, 21005
    • M.I. Pyrogov VNMU Ch of Psych&Nar BO CI O.I. Yuschenko VRPsH
• United Kingdom
  • Birmingham, United Kingdom, B23 6DW
    • Northcroft
  • Edinburgh, United Kingdom, EH10 5HF
    • Royal Edinburgh Hospital
  • Strathclyde
    • Aberdeen, Strathclyde, United Kingdom, AB25 2ZH
      • Royal Cornhill Hospital
• United States
  • Alabama
    • Dothan, Alabama, United States, 36303
      • Harmonex Neuroscience Research
  • California
    • Anaheim, California, United States, 92804
      • California Pharmaceutical Research Institute, Inc
    • Bakersfield, California, United States, 93311
      • Central Valley Medical Research
    • Culver City, California, United States, 90230
      • ProScience Research Group
    • Downey, California, United States, 90241
      • Diligent Clinical Trials, Inc
    • Garden Grove, California, United States, 92845
      • Collaborative Neuroscience Network, LLC
    • Irvine, California, United States, 92614
      • Global Clinical Trials, LLC
    • Orange, California, United States, 92868
      • Neuropsychiatric Research Center of Orange County
    • Panorama City, California, United States, 91402
      • Asclepes Research
    • Riverside, California, United States, 92506
      • CITrials, Inc. - Riverside & San Bernardino County
  • Connecticut
    • Hartford, Connecticut, United States, 06106
      • Hartford Hospital
  • District of Columbia
    • Washington, District of Columbia, United States, 20010
      • Children's National Medical Center
  • Florida
    • Bradenton, Florida, United States, 34201
      • Florida Clinical Research Center, LLC
    • Gainesville, Florida, United States, 32607
      • Sarkis Clinical Trials - Parent
    • Orlando, Florida, United States, 32803
      • Apg Research, Llc
    • Sanford, Florida, United States, 32771
      • Medical Research Group of Central Florida
  • Georgia
    • Atlanta, Georgia, United States, 30308
      • Atlanta Center for Medical Research
    • Smyrna, Georgia, United States, 30080
      • Institute For Behavioral Medicine, Llc
  • Illinois
    • Naperville, Illinois, United States, 60563
      • Baber Research Group
  • Louisiana
    • Lake Charles, Louisiana, United States, 70629
      • Lake Charles Clinical Trials, LLC
  • Maryland
    • Baltimore, Maryland, United States, 21205
      • Kennedy Krieger Institute
  • Michigan
    • Bloomfield Hills, Michigan, United States, 48302
      • Neurobehavioral Medicine Group, PLLC
  • New Jersey
    • Neptune, New Jersey, United States, 07753
      • Jersey Shore University Medical Center
  • New York
    • New York, New York, United States, 10022
      • Manhattan Behavioral Medicine, LLC
    • Rochester, New York, United States, 14618
      • Finger Lakes Clinical Research
    • Staten Island, New York, United States, 10312
      • Richmond Behavioral Associates
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • University of Cincinnati Medical Center
    • Cleveland, Ohio, United States, 44106
      • University Hospitals Case Medical Center
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73116
      • Cutting Edge Research Group
  • Tennessee
    • Memphis, Tennessee, United States, 38119
      • Research Strategies of Memphis, LLC
  • Texas
    • Austin, Texas, United States, 78759
      • BioBehavioral Research of Austin
    • Dallas, Texas, United States, 75243
      • Pillar Clinical Research, LLC
    • El Campo, Texas, United States, 77437
      • BioBehavioral Research of Austin
    • The Woodlands, Texas, United States, 77381
      • Family Psychiatry of The Woodlands, P.A.
  • Utah
    • Orem, Utah, United States, 84058
      • Aspen Clinical Research
  • Virginia
    • Charlottesville, Virginia, United States, 22903
      • University of Virginia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 13 years to 17 years (CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' adherence to the study procedures must be obtained for subjects who are not emancipated. In accordance with Institutional Review Board (IRB) requirements, the subject will complete an informed assent prior to study participation.
• Male or female subjects 13 to 17 years of age, inclusive, at the time of consent.
• DSM-IV-TR axis I primary diagnosis of schizophrenia (including disorganized (295.10), paranoid (295.30), undifferentiated (295.90) subtypes) and confirmation of the schizophrenia diagnosis by an adequately trained clinician at the time of screening, by means of the Schedule for Affective Disorders and Schizophrenia for School-age Children (K-SADS-PL).
• PANSS total score ≥ 70 at screening and Baseline.
• CGI-S ≥ 4 at screening and Baseline.
• Within 5th to 95th percentile for gender specific weight-for-age and height-for-age Growth Charts from National Center for Health Statistics.
• In good physical health on the basis of medical history, physical examination, and laboratory screening.
• Females who participate in this study:

are unable to become pregnant (eg, premenarchal, surgically sterile, etc.); -OR-

practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 30 days after the last dose of study drug has been taken;

-OR-

are sexually active and willing to use a medically effective method of birth control (e.g., male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.

• Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 30 days after the last dose of study drug has been taken.
• In the judgement of the clinician, the subject has an acute exacerbation of psychotic symptoms (no longer than 2 months in duration) and marked deterioration of function from baseline (by history) or, the subject has been hospitalized for the purpose of treating an acute psychotic exacerbation for 2 consecutive weeks or less immediately before screening.
• In the judgment of the investigator, the subject is able to swallow the size and number of study drug tablets specified per protocol.
• Willing and able to adhere to protocol-specified meal requirements during dosing.

Exclusion Criteria:

• Has an Axis I or Axis II diagnosis other than schizophrenia that has been the primary focus of treatment within 3 months of screening.
• Has a history or current diagnosis of mental retardation, neuroleptic malignant syndrome, or any neurologic disorder, or severe head trauma.
• Lifetime history of human immunodeficiency virus (HIV) positive or acquired immune deficiency syndrome (AIDS), or history of Hepatitis B or C.
• Any of the following:

Documented history of chromosomal disorder with developmental impairment (ie, trisomy chromosome 21; 22q11 deletion syndrome).

Evidence of any chronic organic disease of the CNS such as tumors, inflammation, active seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood- eg, Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders. In addition, subjects must not have a history of persistent neurological symptoms attributable to serious head injury. Past history of febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is not exclusionary.

• PANSS total scores ≥ 120 at screening or Baseline.
• Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.
• Lifetime history of electroconvulsive therapy (ECT).
• Resistant to antipsychotic treatment based on at least two different prior adequate trials (ie, adequate dose and duration) of an antipsychotic agent within the current episode of schizophrenia.
• Clinically significant neurological, metabolic (including type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, carcinoma, and/or urological disorder that would pose a risk to the subjects if they were to participate in the study or that might confound the results of the study.

Note: Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Monitor should be consulted. Any subject with a known cardiovascular disease or condition (even if controlled) must be discussed with the Medical Monitor during screening.

• Has a history of malignancy < 5 years prior to signing the informed consent.
• Clinically significant finding(s) on physical examination determined by the investigator to pose a health concern to the subject while on study.
• Clinically relevant abnormal laboratory values or abnormal vital sign values/findings.

Note: If any laboratory results are outside the normal range, the site may have the subject retested. If upon retesting the value remains outside the normal range, the significance of this value must be discussed with the Medical Monitor for enrollment consideration.

• A history or presence of abnormal ECG, which in the investigator's opinion is clinically significant. Abnormal screening ECGs will be centrally over-read, and eligibility will be determined based on the over-read.
• Presence or history (within the last year) of a medical or surgical condition (eg, gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
• Clinically significant alcohol abuse/dependence or drug abuse/dependence based on DSM-IV-TR criteria within the last 6 months prior to screening.

• Positive test results at screening or Baseline for:

  1. Urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, cannabinoids, and methadone). A positive test for amphetamines, barbiturates, opiates, benzodiazepines or methadone may not result in exclusion of subjects if the investigator determines that the positive test is as a result of taking prescription medicine(s) as prescribed. In the event a subject tests positive for cannabinoids (tetrahydrocannabinol) or alcohol, the investigator will evaluate the subject's ability to abstain from prohibited substances during the study. If in the investigator's clinical judgment the subject will abstain, the subject may be enrolled after consultation with the Medical Monitor.
  2. Pregnancy test.
• Females who are pregnant, lactating, or likely to become pregnant during the study.
• Participated in another interventional clinical trial or receiving an investigational product within 30 days prior to randomization.
• Donation of whole blood within 60 days prior to randomization.
• Known history or presence of clinically significant intolerance to any antipsychotic medications including but not limited to angioedema, serotonin or neuroleptic malignant syndromes.
• Clinically relevant history of drug hypersensitivity to lurasidone or any components in the formulation.
• Use of concomitant medications that consistently prolong the QT/QTc interval within 28 days prior to randomization.
• Received depot neuroleptics unless the last injection was at least 1 month or 1 treatment cycle prior to screening, whichever is longer.
• Received treatment with antidepressants, stimulants, or atomoxetine within 3 days prior to randomization, fluoxetine hydrochloride within 21 days of randomization, monoamine oxidase (MAO) inhibitor within 28 days of randomization, or clozapine within 120 days of randomization.
• Use of any antipsychotic medication (other than study drug), carbamazepine, oxcarbazepine, eslicarbazepine acetate, or fluvoxamine, within 3 days prior to randomization (7 days prior to randomization for aripiprazole) and until follow-up.
• Has a prolactin concentration ≥ 100 ng/mL at screening, or has a history of pituitary adenoma.
• At screening or Baseline the subject answers "yes" to "Suicidal Ideation" Items 4 or 5 on the C-SSRS.
• Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property during the study. Subject has a history of one or more serious suicide attempts (based on the investigator's judgment) in the 3 months prior to screening. Subjects determined to be at risk of suicide or injury, as assessed by the investigator at screening, will be referred for further psychiatric evaluation.
• Adhering to a special diet for the 28 days prior to drug administration (eg, liquid, protein, raw food diet).
• Subject is planning to move during the study, is chronically homeless, or is unable to attend all planned study visits. The Medical Monitor will be consulted for individual cases, as needed.
• Demonstrates a decrease (improvement) of > 25% in the PANSS score between screening and Baseline visits.
• Subject with newly diagnosed Type 2 diabetes during screening. A subject with Type 2 diabetes is eligible for study inclusion if considered clinically stable, which is defined as:

Random (non-fasting) screening glucose is < 200 mg/dl (11.1 mmol/L); and If ≥ 200 mg/dL (11.1 mmol/L) must be retested in a fasted state. Retested fasted value cannot be ≥ 126 mg/dL.

HbA1c ≤ 6.5%; and If a subject is currently being treated with oral anti-diabetic medication(s), the dose must have been stable for at least 4 weeks prior to screening. Such medication may be adjusted or discontinued during the study, as clinically indicated.

• Subject has required hospitalization for diabetes or related complications in the past 12 months.
• Subject requires use of concomitant medications that are potent inducers or inhibitors of the cytochrome P450 (CYP) 3A4 enzyme system (Appendix C) from signing informed consent until follow-up.
• Clinically significant orthostatic hypotension (ie., a drop in systolic blood pressure of 20 mmHg or more and/or drop in diastolic blood pressure of 10 mmHg or more within 4 minutes of standing up).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lurasidone 40 mg; Lurasidone 40 mg once daily	Drug: Lurasidone 40 mg; Lurasidone 40 mg once daily; Other Names: Latuda
Experimental: Lurasidone 80 mg; Lurasidone 80 mg once daily Arm received the Lurasidone 40mg dose first, from Days 1-3, and then received the Lurasidone 80 mg dose from day 4 to Week 6	Drug: Lurasidone 80 mg; Lurasidone 80 mg once daily; Other Names: Latuda
Placebo Comparator: Placebo; Placebo 40 or 80 mg once daily	Drug: Placebo 40 or 80 mg; Placebo 40 or 80 mg once daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6.	PANNS total score: Changes from baseline over time - mixed model for repeated measures at week 6 -PANSS total score may range from 30 to 210- Higher values of PANSS total score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, PANSS total score at baseline, and treatment-by-visit interaction.	Baseline to 6 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale	Clinical Global Impression severity (CGI-S): Changes from baseline over time-mixed model for repeated measures- scale from 1-7 - 1=normal, not at all ill; 7=among the most extremely ill patients. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, CGIS at baseline, and treatment-by-visit interaction.	baseline, week 6
Change From Baseline in PANSS Positive Subscale Scores	PANSS positive subscale score: changes from baseline over time - mixed model for repeated measures -Positive subscale (range 7-49): sum of Items P1 to P7 in the positive subscale - Higher values of PANSS Positive Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.	baseline, week 6
Change From Baseline in PANSS Positive, Negative Subscale Scores	PANSS Negative subscale score: changes form baseline over time - Mixed model for repeated measures - - Negative subscale (range 7-49): sum of Items N1 to N7 in the negative subscale - Higher values of PANSS Negative Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.	baseline, week 6
Proportion of Responders, Where Response is Based on ≥ 20% Improvement From Baseline in PANSS Total Score at Week 6	PANSS responder analysis over time: achieving >= 20% reduction from baseline	week 6
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q)	PQ-LES-Q percentage maximum possible score: summary statistics over time - PQ-LES-Q % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life. LS Mean and SE for change from baseline are from an ANCOVA model including factors of treatment, pooled country and age group (stratification factor), and corresponding Baseline score as covariate and LOCF approach.	baseline, week 6
Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS)	Clinician-rated Children's Global Assessment Scale (CGAS) score: summary statistics over time - CGAS is a numeric scale (1 through 100) , where 1 represents the most impaired functioning and 100, superior functioning LS Mean and SE for change from baseline are from an ANCOVA model including factors of treatment, pooled country and age group (stratification factor), and corresponding Baseline score as covariate and LOCF approach.	baseline, week 6
Change From Baseline in PANSS General Psychopathology Subscale Scores	PANSS general psychopathology subscale score: changes from baseline over time - mixed model for repeated measures -- General psychopathology (range 16-112): sum of Items G1 to G16 in the general psychopathology subscale -Higher values of PANSS General Psychopathology Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.	baseline, week 6
Change From Baseline in PANSS Excitability Subscale Scores	Excitability subscale scores (range 4-28): consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control; Higher values of PANSS Excitability Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.	baseline, week 6

Collaborators and Investigators

• Sponsor: Sunovion

Study record dates

Study Major Dates

• Study Start: August 1, 2013
• Primary Completion (Actual): December 1, 2015
• Study Completion (Actual): December 1, 2015

Study Registration Dates

• First Submitted: July 22, 2013
• First Submitted That Met QC Criteria: July 26, 2013
• First Posted (Estimate): July 30, 2013

Study Record Updates

• Last Update Posted (Actual): April 18, 2017
• Last Update Submitted That Met QC Criteria: March 22, 2017
• Last Verified: March 1, 2017

More Information

Terms related to this study

• Keywords: schizophrenia; Lurasidone; Latuda
• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia; Physiological Effects of Drugs; Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Serotonin Agents; Dopamine Agents; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Dopamine D2 Receptor Antagonists; Dopamine Antagonists; Adrenergic alpha-Antagonists; Adrenergic alpha-2 Receptor Antagonists; Lurasidone Hydrochloride
• Other Study ID Numbers: D1050301; 2013-001695-38 (EudraCT Number)